Exploring the NANOG-TET2 interaction interface. Effects of a selected mutation and hypothesis on the clinical correlation with anemias DOI Creative Commons
Claudia Testi, Roberta Piacentini,

Alessandro Perrone

et al.

Frontiers in Chemical Biology, Journal Year: 2025, Volume and Issue: 3

Published: Jan. 6, 2025

In this study, we focused on the computational analysis of a selected single-point mutation identified by NGS screening panel in TET2 enzyme classified as “variant uncertain clinical significance.” The mutation, namely Q1084P, occurs at interface between TET2, an important epigenetic regulator, and NANOG, transcription factor fundamental for hematopoietic cells differentiation. Notably, protein region distant from active site; moreover, experimental structures interacting both proteins are unknown, making it difficult to validate impact its binding with NANOG. To address these challenges, employed integrated approach combining molecular docking, dynamics simulations protein-protein interaction prediction. Our findings indicate that might effectively reduce TET2-NANOG interaction, which would consequently impair differentiation hematopoiesis process, consistent presentation pure red cell aplastic anemia. These results, along proposed method, provide insights establishing correlations variants significance anemias general, comprising common hematological problems widespread world population dedicated panels still not available.

Language: Английский

Biomolecular condensates in immune cell fate DOI
Srikanth Kodali, Caroline M. Sands, Lei Guo

et al.

Nature reviews. Immunology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 28, 2025

Language: Английский

Citations

1
Tumor Metastasis: Mechanistic Insights and Therapeutic Intervention DOI Creative Commons

Lin Tang,

Peng Shen, Xiaoying Zhuang

et al.

MedComm – Oncology, Journal Year: 2025, Volume and Issue: 4(1)

Published: Feb. 17, 2025

ABSTRACT Metastasis remains a leading cause of cancer‐related deaths, defined by complex, multi‐step process in which tumor cells spread and form secondary growths distant tissues. Despite substantial progress understanding metastasis, the molecular mechanisms driving this development effective therapies remain incompletely understood. Elucidating pathways governing metastasis is essential for discovery innovative therapeutic targets. The rapid advancements sequencing technologies expansion biological databases have significantly deepened our drivers associated drug resistance. This review focuses on particularly roles genetic mutations, epigenetic changes, post‐translational modifications progression. We also examine how microenvironment influences metastatic behavior explore emerging strategies, including targeted immunotherapies. Finally, we discuss future research directions, stressing importance novel treatment approaches personalized strategies to overcome improve patient outcomes. By integrating contemporary insights into basis innovation, provides comprehensive framework guide clinical cancer.

Language: Английский

Citations

1
Enhancer‐dependent gene regulation in space, time, and malignancies DOI Creative Commons

Beat Blum,

Victoria Dachtler,

Angelika Feldmann

et al.

International Journal of Cancer, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 31, 2025

Control of cell-type-specific gene activation requires the coordinated activity distal regulatory elements, including enhancers, whose inputs must be temporally integrated. Dysregulation this capacity, such as aberrant usage can result in malignant transformation cells. In review, we provide an overview our current understanding enhancer-driven regulation and discuss how may integrated across time, followed by epigenetic structural alterations enhancers cancers.

Language: Английский

Citations

0
piRNAs in leukemogenesis: Mechanisms, biomarkers, and therapeutic implications DOI
Gaurav Gupta, Muhammad Afzal, Ahsas Goyal

et al.

Clinica Chimica Acta, Journal Year: 2025, Volume and Issue: unknown, P. 120220 - 120220

Published: March 1, 2025

Language: Английский

Citations

0
Exploring the NANOG-TET2 interaction interface. Effects of a selected mutation and hypothesis on the clinical correlation with anemias DOI Creative Commons
Claudia Testi, Roberta Piacentini,

Alessandro Perrone

et al.

Frontiers in Chemical Biology, Journal Year: 2025, Volume and Issue: 3

Published: Jan. 6, 2025

In this study, we focused on the computational analysis of a selected single-point mutation identified by NGS screening panel in TET2 enzyme classified as “variant uncertain clinical significance.” The mutation, namely Q1084P, occurs at interface between TET2, an important epigenetic regulator, and NANOG, transcription factor fundamental for hematopoietic cells differentiation. Notably, protein region distant from active site; moreover, experimental structures interacting both proteins are unknown, making it difficult to validate impact its binding with NANOG. To address these challenges, employed integrated approach combining molecular docking, dynamics simulations protein-protein interaction prediction. Our findings indicate that might effectively reduce TET2-NANOG interaction, which would consequently impair differentiation hematopoiesis process, consistent presentation pure red cell aplastic anemia. These results, along proposed method, provide insights establishing correlations variants significance anemias general, comprising common hematological problems widespread world population dedicated panels still not available.

Language: Английский

Citations

0